SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
mds25561-sup-0001-suppfig1.eps1421KSUPPORTING FIG. 1. The study design is illustrated. Enrolled patients were randomized to receive 20 mg/day, 50 mg/day, 100 mg/day, 150 mg/day, or 200 mg/day AFQ056 or placebo (1:1:1:1:2:3 ratio) in a 12-week, double-blind treatment phase. Patients were titrated at 1-week intervals to their target or highest tolerated dose. With the exception of the 20 mg/day AFQ056 group, all active-treated patients were initiated on 50 mg/day AFQ056. At the beginning of week 13, active-treated patients were randomized to a 1-week taper-off regimen with AFQ056 or placebo. The 20 mg/day AFQ056 group received 20 mg/day AFQ056 or placebo for 1 week, and the 50 mg/day AFQ056 group received 50 mg/day AFQ056 or placebo for 1 week. The 100 mg/day, 150 mg/day, and 200 mg/day AFQ056 groups received either 100 mg/day AFQ056 for 3 days followed by 50 mg/day AFQ056 for 4 days (1 week total duration) or placebo for 1 week.
mds25561-sup-0002-supptab1.doc32KSupporting Table 1. Summary of the final actual dose of AFQ056 received at the end of the treatment phase, by randomized dose
mds25561-sup-0003-suppinfo.doc54KSupporting Information.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.